Navigation Links
Amgen to Highlight New Evolocumab (AMG 145) Data at Upcoming American Heart Association Scientific Sessions 2013
Date:11/12/2013

THOUSAND OAKS, Calif., Nov. 12, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that it will present new data on evolocumab (AMG 145), an investigational fully human monoclonal antibody that inhibits PCSK9, a protein that reduces the liver's ability to remove low-density lipoprotein cholesterol (LDL-C), or "bad" cholesterol, from the blood1, at the upcoming American Heart Association (AHA) Scientific Sessions 2013, being held Nov. 16 – 20 in Dallas.

Data from the Phase 2 OSLER (Open Label Study of Long TERm Evaluation Against LDL-C Trial) study, which evaluates the safety, tolerability and sustained efficacy of long-term administration of evolocumab and standard of care in more than 1,100 patients with high cholesterol, will be featured during a Clinical Science: Special Reports session on Tuesday, Nov. 19, at 4:51 p.m. CST.

"The Phase 2 OSLER study provides the first long-term 52-week data for a PCSK9 inhibitor in diverse patient populations with high cholesterol," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. "We hope the data we are accumulating from our Phase 3 clinical program for evolocumab will help advance care for patients who struggle to control high cholesterol and have an urgent unmet need."

Additionally, Amgen will highlight findings from long-term open-label data accumulated from patients in GAUSS (Goal Achievement after Utilizing an anti-PCSK9 antibody in Statin intolerant Subjects) and MENDEL (Monoclonal Antibody Against PCSK9 to Reduce Elevated LDL-C in Patients Currently Not Receiving Drug Therapy For Easing Lipid Levels), two Phase 2 studies that evaluated evolocumab in patients with
'/>"/>

SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Amgen and Onyx Pharmaceuticals Announce Upcoming Data Presentations at 55th American Society of Hematology Annual Meeting
2. Amgen Presents New Data From Phase 3 Study Of Talimogene Laherparepvec In Patients With Metastatic Melanoma
3. Amgen And ShanghaiTech University Announce Plans For Amgen China R&D Center To Open On ShanghaiTech Campus
4. Amgen And Servier Complete Product Collaboration Transaction
5. Amgen Announces 2013 Third Quarter Dividend
6. Technical Briefing: Amgen, PDL BioPharma, Questcor Pharma, and BioCryst Pharma
7. Amgen And Servier Announce Product Collaboration
8. Amgen Joins BlackLine Systems, SAP for Webinar on Automating Account Reconciliations
9. Amgen And AstraZeneca Highlight Data To Be Presented At European League Against Rheumatism Annual Meeting
10. Amgen Announces Top-Line Results Of Phase 3 Talimogene Laherparepvec Trial In Melanoma
11. Amgen Announces 2013 Second Quarter Dividend
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/22/2014)... 2014 On November 17th Chicago start-up ... Emerging Medical Technologies Summit in San Francisco to take ... regarded among Silicon Valley investors and technology elites as ... win also positions Briteseed to move on to ... 2015 and compete with other elite innovation finalists for ...
(Date:11/21/2014)... November 21, 2014 , ...   Mariano Rodríguez es elegid vicepresidente senior ... KLOX está en marcha para comenzar de forma rápida ... heridas de reciente aprobación en Europa   , ... complace al anunciar los siguientes nombramientos: Todd ...
(Date:11/21/2014)... Calif. (PRWEB) November 20, 2014 ... nonprofit, public policy research organization representing leading California ... firms, and PwC US today released ... in life sciences industry growth. The trend shows ... The 2015 California Biomedical Industry Report ...
(Date:11/21/2014)... 21, 2014 2014 Deep Research ... is a professional and in-depth research report on ... information, like its definition, classification, application, and ... This report covers the international market analysis, including ... as the US, Europe, Asia, China, Japan etc. ...
Breaking Biology Technology:Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 2Insight Product Development Accelerator Member Wins MedTech Innovator Award Competition 3KLOX Technologies anuncia sus nombramientos ejecutivos 2KLOX Technologies anuncia sus nombramientos ejecutivos 3KLOX Technologies anuncia sus nombramientos ejecutivos 4KLOX Technologies anuncia sus nombramientos ejecutivos 5California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 2California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 3California Healthcare Institute and PwC Report Boom in California’s Biomedical Industry 4Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 2Sodium Ferrocyanide Market: Analysis for Global & China Regions Development Trends Available at DeepResearchReports.com 3
... , , , Multiporator / Electroporator 2510 , , , , ... Transformation Protocol , Protocol No. 4308 915.536 ... , , , , , ... fbd11, protoplasts, , , ...
... , , , , , Multiporator , , , , ... Transfection Protocol , Protocol No. 4308 915.040 11/2000 , ... , , , Cell line ... Transfection with , Plasmid pEGFP-C1 (in bidistilled H 2 O), ...
... , , Multiporator / Electroporator 2510 , , , , , , ... Transformation Protocol , Protocol No. 4308 915.534 01/2002 , , ... , , Microorganism , ... Cell type , Bacteria, gram positive, ...
Cached Biology Technology:Ustilago maydis 2Ustilago maydis 3U-266 2Staphylococcus epidermidis 2
(Date:11/4/2014)...   Neurotechnology , a provider of high-precision ... version of its fingerprint matching algorithm has achieved ... evaluation organized by NIST. The MINEX test measures ... 378 fingerprint standard template format. MINEX compliance is ... the United States and ...
(Date:11/3/2014)... LOS ANGELES , Nov. 3, 2014 /PRNewswire/ ... California -based life sciences company focused on ... eTNS system for the treatment of neurological ... Institute of Industrial Property has issued a Notice ... The patent application is co-owned by NeuroSigma and ...
(Date:11/2/2014)... 2014)—In support of a bold quest to rid the ... Foundation today announced an award of US$156 million to ... in building new vaccines that will interrupt the cycle ... to zero" agenda. Such vaccines would ensure that parasite ... an "immunological bed net." , This approach to ...
Breaking Biology News(10 mins):Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 2Neurotechnology Places Second in Ongoing MINEX Ranking for Fingerprint Matching Algorithms 3NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 2NeuroSigma Receives Notice of Allowance from the Mexican Institute of Industrial Property Covering Subcutaneous Trigeminal Nerve Stimulation (sTNS) 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 2New malaria vaccines to prevent infection and block transmission get a shot in the arm 3New malaria vaccines to prevent infection and block transmission get a shot in the arm 4
... Evolved Machines, Inc. has,been selected as a ... Research,Projects Agency (DARPA) program to engineer an ... The $5.1 million,dollar contract will integrate work ... highly versatile and sensitive broad-spectrum device capable ...
... plastic limbs and metal rods to complex virtual humans made ... yesteryear are evolving and researchers at Wake Forest University School ... This new generation of human body models will represent ... "dummies" before. The models will contain detailed representation of the ...
... the focus of two federal grants totaling $3.2 million ... work together on a pair of multi-site projects designed ... from wildfires in the face of a changing climate. ... Center for Ecology and Evolutionary Biology, will lead an ...
Cached Biology News:Wake Forest plays integral role in effort to revolutionize vehicle safety 2Wake Forest plays integral role in effort to revolutionize vehicle safety 3Northwest climate change is target of $3.2M in grants to University of Oregon 2Northwest climate change is target of $3.2M in grants to University of Oregon 3Northwest climate change is target of $3.2M in grants to University of Oregon 4